Perri Giorgia, Hill Tom R, Mathers John C, Walsh Jennifer S, Gossiel Fatma, Winther Kristian, Frölich Jacob, Folkestad Lars, Cold Søren, Eastell Richard
Human Nutrition Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
J Bone Miner Res. 2022 Nov;37(11):2165-2173. doi: 10.1002/jbmr.4703. Epub 2022 Sep 29.
Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long-term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N-terminal propeptide (PINP), collagen type I cross-linked C-telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60-74 years) were randomized to receive placebo-yeast versus 100, 200, or 300 μg selenium as selenium-enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose-response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p < 0.001)). There was no change in plasma selenium concentration in the placebo-treated group. There was no significant effect of selenium supplementation on OC (6 months p = 0.37; 5 years p = 0.63), PINP (6 months p = 0.37; 5 years p = 0.79), CTX (6 months p = 0.91; 5 years p = 0.58) or BALP (6 months p = 0.17; 5 years p = 0.53). The relatively replete baseline selenium status in the study participants may explain this lack of effect. Testing in more deficient populations may provide further insights into the impact of selenium supplementation on bone health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
在流行病学研究中,较高的硒水平与较低的骨转换标志物(BTM)相关。然而,补充硒对骨转换标志物的长期影响尚未得到研究。我们调查了补充硒在短期(6个月)和长期(5年)对骨转换标志物的影响,这些标志物包括骨钙素(OC)、I型前胶原N端前肽(PINP)、I型胶原交联C端肽(CTX)和骨碱性磷酸酶(BALP)。共有481名丹麦男性和女性(60 - 74岁)被随机分组,分别接受安慰剂酵母或每日100、200或300μg硒的富硒酵母,持续5年。使用电感耦合等离子体质谱法测量血浆硒浓度,并在基线、6个月和5年时对非空腹样本测量骨转换标志物。通过协方差分析(ANCOVA)分析数据,以研究剂量反应关系的形状。协变量包括年龄、体重指数、基线硒状态、基线骨转换标志物、吸烟、饮酒、补充剂使用和药物治疗。血浆硒浓度(基线时平均为86.5μg/d)随着硒补充量的增加而显著升高,6个月后分别升至152.6、209.1和253.7μg/L,并在5年时保持升高(每日补充100、200和300μg硒时分别为158.4、222.4和275.9μg/L,p < 0.001)。安慰剂治疗组的血浆硒浓度没有变化。补充硒对骨钙素(6个月时p = 0.37;5年时p = 0.63)、I型前胶原N端前肽(6个月时p = 0.37;5年时p = 0.79)、I型胶原交联C端肽(6个月时p = 0.91;5年时p = 0.58)或骨碱性磷酸酶(6个月时p = 0.17;5年时p = 0.53)均无显著影响。研究参与者相对充足的基线硒状态可能解释了这种无效应的情况。在更缺乏硒的人群中进行测试可能会进一步深入了解补充硒对骨骼健康的影响。© 2022作者。《骨与矿物质研究杂志》由威利期刊有限责任公司代表美国骨与矿物质研究学会(ASBMR)出版。